Home Cart Sign in  
Chemical Structure| 941678-49-5 Chemical Structure| 941678-49-5
Chemical Structure| 941678-49-5

*Storage: Inert atmosphere,Store in freezer, under -20°C.

Ruxolitinib

CAS No.: 941678-49-5

Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50 values of 3.3 nM and 2.8 nM in cell-free assays. It has a 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy.

Synonyms: INCB18424;INCB 018424

4.5 *For Research Use Only !

Cat. No.: A272323 Purity: 98%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
1mg łÇò¶ÊÊ Inquiry Inquiry Login
5mg łË§¶ÊÊ Inquiry Inquiry Login
10mg ł§Ê¶ÊÊ Inquiry Inquiry Login
50mg łÍ˶ÊÊ Inquiry Inquiry Login
100mg łò˶ÊÊ Inquiry Inquiry Login
250mg łÇËò¶ÊÊ In Stock In Stock Login
1g ł§ďò¶ÊÊ In Stock In Stock Login
5g łÇ§Çó¶ÊÊ In Stock In Stock Login

Please Login or Create an Account to: See VIP prices and availability

  • 1mg

    łÇò¶ÊÊ

  • 5mg

    łË§¶ÊÊ

  • 10mg

    ł§Ê¶ÊÊ

  • 50mg

    łÍ˶ÊÊ

  • 100mg

    łò˶ÊÊ

  • 250mg

    łÇËò¶ÊÊ

  • 1g

    ł§ďò¶ÊÊ

  • 5g

    łÇ§Çó¶ÊÊ

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Citations      Show More

Franco, Lucas ; Rodrigues, Daniel ; Baumart, Gabriela , et al.

Abstract: Rho-associated protein kinases (ROCK) play a pivotal role in various cellular processes and have emerged as therapeutic targets for neurodegenerative diseases such as Alzheimer's disease (AD). Inhibition of ROCK affects the production of key AD pathophysiological markers and reduces neuroinflammation. This study aims to accelerate the identification of effective candidates for neurodegeneration by drug repurposing. By conducting chemical space and crystallographic structure analyses, we developed a pharmacophoric map and optimized it to perform a virtual screening campaign. This approach led to the discovery of novel 6 already approved ROCK inhibitors: ruxolitinib (hROCK1IC50 = 0.025 µM; hROCK2IC50 = 0.007 µM), baricitinib (hROCK1IC50 = 0.019 µM; hROCK2IC50 = 0.011 µM), ponatinib (hROCK1IC50 = 0.197 µM; hROCK2IC50 = 0.056 µM), tivozanib (hROCK1IC50 = 12.86 µM; hROCK2IC50 = 0.856 µM), nialamide (hROCK1IC50 = 18.8 µM; hROCK2IC50 = 29.2 µM) and tucatinib (hROCK1IC50 = 51.45 µM; hROCK2IC50 = 18.62 µM). The results of this study highlight ruxolitinib and baricitinib as potent ROCK inhibitors with IC50 values in the low nanomolar range. Tivozanib showed 15-fold selectivity for ROCK2 over ROCK1. Molecular dynamics simulations with ruxolitinib revealed a tight binding with the ATP-binding site of ROCK1 and ROCK2, with stable bidentate hydrogen bonding interactions with the main chain of amino acid residues in the hinge region of ROCK1 and ROCK2. In addition, ruxolitinib showed selectivity for ROCK enzymes across AGC kinase family, highlighting its interesting ROCK/JAK multitarget profile, which can open new avenues in the discovery of novel multitarget-directed ligands for the treatment of neurodegenerative disorders. Biological validation revealed ruxolitinib’s safety profile against different neuronal and glial cell lines. Further, ruxolitinib reduced the immunolabeling for C3, a glial inflammation marker, in LPS-treated astrocytes. This work highlights ruxolitinib as a promising therapeutic option for Alzheimer's disease and other neurodegenerative conditions and pave the way for the new in vitro/in vivo studies for its repurposing.

Keywords: drug repositioning ; virtual screening ; neurodegeneration ; pharmacophore modeling ; JAK inhibitors

Purchased from AmBeed:

Asemota, Sarah ; Effah, Wendy ; Young, Kirsten L. , et al.

Abstract: Triple-neg. breast cancer (TNBC) is an aggressive subtype with no targeted therapeutics. The luminal androgen receptor (LAR) subtype constitutes 15% of TNBC and is enriched for androgen receptor (AR) and AR target genes. Here, we show that a cohort of TNBC not only expresses AR at a much higher rate (∼80%) but also expresses AR splice variants (AR-SVs) (∼20%), further subclassifying LAR-TNBC. Higher AR and AR-SV expression and corresponding aggressive phenotypes are observed predominantly in specimens obtained from African American women. LAR TNBC specimens are enriched for interferon, Janus kinase (JAK)-signal activator and transducer (STAT), and androgen signaling pathways, which are exclusive to AR-expressing epithelial cancer cells. AR- and AR-SV-expressing TNBC cell proliferation and xenograft and patient-tumor explant growth are inhibited by AR N-terminal domain-binding selective AR degrader or by a JAK inhibitor. Biochem. anal. suggests that STAT1 is an AR coactivator. Collectively, our work identifies pharmacol. targetable TNBC subtypes and identifies growth-promoting interaction between AR and JAK-STAT signaling.

Purchased from AmBeed:

Leclercq, Gabrielle ; Haegel, Hélène ; Toso, Alberto , et al.

Abstract: Background: T cell engaging therapies, like chimeric antigen receptor T cells and T cell bispecific antibodies (TCBs), efficiently redirect T cells towards tumor cells, facilitating the formation of a cytotoxic synapse and resulting in subsequent tumor cell killing, a process that is accompanied by the release of cytokines. Despite their promising efficacy in the clinic, treatment with TCBs is associated with a risk of cytokine release syndrome (CRS). The aim of this study was to identify small molecules able to mitigate cytokine release while retaining T cell-mediated tumor killing. Methods: By screening a library of 52 Food and Drug Administration approved kinase inhibitors for their impact on T cell proliferation and cytokine release after CD3 stimulation, we identified mTOR, JAK and Src kinases inhibitors as potential candidates to modulate TCB-mediated cytokine release at pharmacologically active doses. Using an in vitro model of target cell killing by human peripheral blood mononuclear cells, we assessed the effects of mTOR, JAK and Src kinase inhibitors combined with 2+1 T cell bispecific antibodies (TCBs) including CEA-TCB and CD19-TCB on T cell activation, proliferation and target cell killing measured by flow cytometry and cytokine release measured by Luminex. The combination of mTOR, JAK and Src kinase inhibitors together with CD19-TCB was evaluated in vivo in non-tumor bearing stem cell humanized NSG mice in terms of B cell depletion and in a lymphoma patient-derived xenograft (PDX) model in humanized NSG mice in terms of antitumor efficacy. Results: The effect of Src inhibitors differed from those of mTOR and JAK inhibitors with the suppression of CD19-TCB-induced tumor cell lysis in vitro, whereas mTOR and JAK inhibitors primarily affected TCB-mediated cytokine release. Importantly, we confirmed in vivo that Src, JAK and mTOR inhibitors strongly reduced CD19-TCB-induced cytokine release. In humanized NSG mice, continuous treatment with a Src inhibitor prevented CD19-TCB-mediated B cell depletion in contrast to mTOR and JAK inhibitors, which retained CD19-TCB efficacy. Ultimately, transient treatment with Src, mTOR and JAK inhibitors minimally interfered with antitumor efficacy in a lymphoma PDX model. Conclusions: Taken together, these data support further evaluation of the use of Src, JAK and mTOR inhibitors as prophylactic treatment to prevent occurrence of CRS.

Purchased from AmBeed: ; ; ; ;

Brown, Richard J. P. ; Tegtmeyer, Birthe ; Sheldon, Julie , et al.

Abstract: Hepatitis C virus (HCV) has no animal reservoir, infecting only humans. To investigate species barrier determinants limiting infection of rodents, murine liver complementary DNA library screening was performed, identifying transmembrane proteins Cd302 and Cr1l as potent restrictors of HCV propagation. Combined ectopic expression in human hepatoma cells impeded HCV uptake and cooperatively mediated transcriptional dysregulation of a noncanonical program of immunity genes. Murine hepatocyte expression of both factors was constitutive and not interferon inducible, while differences in liver expression and the ability to restrict HCV were observed between the murine orthologs and their human counterparts. Genetic ablation of endogenous Cd302 expression in human HCV entry factor transgenic mice increased hepatocyte permissiveness for an adapted HCV strain and dysregulated expression of metabolic process and host defense genes. These findings highlight human-mouse differences in liver-intrinsic antiviral immunity and facilitate the development of next-generation murine models for preclin. testing of HCV vaccine candidates.

Purchased from AmBeed:

Product Details of [ Ruxolitinib ]

CAS No. :941678-49-5
Formula : C17H18N6
M.W : 306.37
SMILES Code : N#CC[C@]([H])(C1CCCC1)N2C=C(C=N2)C3=C4C=CN=C4NC=N3
Synonyms :
INCB18424;INCB 018424
MDL No. :MFCD12031592
InChI Key :HFNKQEVNSGCOJV-OAHLLOKOSA-N
Pubchem ID :25126798

Safety of [ Ruxolitinib ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of [ Ruxolitinib ]

epigenetics
RTK
JAK-STAT

ALK Isoform Comparison

Name JAK1 JAK2 JAK3 Tyk2 Purity
Peficitinib 98%
Go6976 98%
AZD-1480 ++++

JAK2, IC50: 0.26 nM

98+%
Ruxolitinib +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

98%
Fedratinib +++

JAK2 (V617F), IC50: 3 nM

JAK2, IC50: 3 nM

98%
WP1066 +

JAK2, IC50: 2.3 μM

98%
Curcumol 98%
AZ960 ++++

JAK2, Ki: 0.45 nM

JAK2, IC50: <3 nM

97%
GLPG0634 analog 99%
CEP-33779 ++++

JAK2, IC50: 1.8 nM

99%
FLLL32 +

JAK2, IC50: <5 μM

98%
WHI-P154 +

JAK3, IC50: 1.8 μM

98%
Decernotinib +++

JAK1, IC50: 11 nM

JAK1, Ki: 11 nM

+++

JAK2, Ki: 13 nM

++++

JAK3, Ki: 2.5 nM

+++

TYK2, Ki: 13 nM

99%
ZM39923 HCl +

JAK1, pIC50: 4.4

+

JAK3, pIC50: 7.1

97%
Cerdulatinib +++

JAK1, IC50: 12 nM

+++

JAK2, IC50: 6 nM

+++

JAK3, IC50: 8 nM

++++

TYK2, IC50: 0.5 nM

98%
TG101209 +++

JAK2, IC50: 6 nM

+

JAK3, IC50: 169 nM

99%
AT9283 ++++

JAK2, IC50: 1.2 nM

++++

JAK3, IC50: 1.1 nM

98%
Momelotinib +++

JAK1, IC50: 11 nM

++

JAK2, IC50: 18 nM

+

JAK3, IC50: 155 nM

98+%
XL019 +

JAK1, IC50: 134.3 nM

++++

JAK2, IC50: 2.2 nM

+

JAK3, IC50: 214.2 nM

98%
Tofacitinib +

JAK1, IC50: 112 nM

++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

98%
Filgotinib +++

JAK1, IC50: 10 nM

++

JAK2, IC50: 28 nM

+

JAK3, IC50: 810 nM

+

TYK2, IC50: 116 nM

99%
Pacritinib ++

JAK2 (V617F), IC50: 19 nM

JAK2, IC50: 23 nM

+

JAK3, IC50: 520 nM

++

TYK2, IC50: 50 nM

97%
Gandotinib ++

JAK1, IC50: 19.8 nM

++++

JAK2 (V617F), Ki: 0.245 nM

JAK2, IC50: 0.288 nM

++

JAK3, IC50: 48.0 nM

++

TYK2, IC50: 44 nM

98%
Tofacitinib citrate ++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

99%
Oclacitinib maleate +++

JAK1, IC50: 10nM

++

JAK2, IC50: 18nM

+

JAK3, IC50: 99nM

+

TYK2, IC50: 84nM

98+%
NVP-BSK805 2HCl ++

JAK1, IC50: 31.63 nM

++++

JAK2, IC50: ~0.5 nM

++

JAK3, IC50: 18.68 nM

+++

TYK2, IC50: 10.76 nM

99+%
FM-381 ++++

JAK3, IC50: 127 pM

98%
Ruxolitinib (S enantiomer) +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

++

TYK2, IC50: 19 nM

98%
Baricitinib +++

JAK1, IC50: 5.9 nM

+++

JAK2, IC50: 5.7 nM

++

TYK2, IC50: 53 nM

99%

Biological Activity

Target
  • JAK1

    JAK1, IC50:3.3 nM

  • JAK2

    JAK2, IC50:2.8 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03274778 Prostate Cancer Not Applicable Recruiting May 1, 2019 Switzerland ... More >> Istituto Oncologico della Svizzera Italiana (IOSI) Recruiting Bellinzona, Switzerland, 6500 Contact: Ricardo Pereira Mestre, Dr. med.    +41 (0)91 811 84 46    Ricardo.PereiraMestre@eoc.ch    Contact: Barbara Marongiu    +41 (0)91 811 91 20    barbara.marongiu@eoc.ch Less <<
NCT02120417 - Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << - -
NCT01914484 Chronic Phase Chronic Myeloid ... More >>Leukemia Accelerated Phase Chronic Myeloid Leukemia Blastic Phase Chronic Myeloid Leukemia Philadelphia Positive Acute Lymphoblastic Leukemia Resistant to Tyrosine Kinase Inhibitor Therapy Less << Phase 1 Phase 2 Unknown July 2016 Canada, Ontario ... More >> Princess Margaret Hospital / University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Sima Bogomilsky, RN BScN CON(C)    416-946-4646    sima.bogomilsky@uhn.on.ca    Contact: Sonal Malhotra, M.Sc., Ph.D,CCRP    416-946-4501 ext 3449    sonal.malhotra@uhn.ca    Principal Investigator: Dennis Kim, MD/PhD          Sub-Investigator: Jeffrey H Lipton, MD/PhD Less <<
NCT02119650 - Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << - -
NCT03257644 Atopic Dermatitis Phase 1 Suspended(Study is currently o... More >>n hold pending amendment update.) Less << December 2019 United States, California ... More >> Children's Hospital of Los Angeles Los Angeles, California, United States, 90027 Rady Children's Hospital - San Diego San Diego, California, United States, 92123 United States, Colorado National Jewish Health Denver, Colorado, United States, 80206 United States, Illinois Northwestern University Department of Dermatology Chicago, Illinois, United States, 60611 United States, Michigan David Fivenson, MD, Dermatology, PLC Ann Arbor, Michigan, United States, 48103 United States, North Carolina Wake Research Associates Raleigh, North Carolina, United States, 27612 United States, Pennsylvania Penn State Hershey Medical Center Hershey, Pennsylvania, United States, 17033 United States, Texas Texas Dermatology and Laser Specialist Clinical Research San Antonio, Texas, United States, 78218 Less <<
NCT03654768 Chronic Phase Chronic Myelogen... More >>ous Leukemia, BCR-ABL1 Positive Less << Phase 2 Recruiting January 1, 2026 United States, Oregon ... More >> SWOG Recruiting Portland, Oregon, United States, 97239 Contact: Kendra L. Sweet    813-745-6841    kendra.sweet@moffitt.org    Principal Investigator: Kendra L. Sweet Less <<
NCT02593760 Myelofibrosis Phase 1 Completed - United States, Florida ... More >> Florida Cancer Specialists-Broadway, Fort Myers Fort Myers, Florida, United States, 33908 Florida Cancer Specialist, North Region Saint Petersburg, Florida, United States, 33705 Florida Cancer Specialists West Palm Beach, Florida, United States, 33401 United States, Ohio Oncology Hematology Care Inc Cincinnati, Ohio, United States, 45242 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas Uni of Texas - Md Anderson Cancer Center; Dept of Leukemia Houston, Texas, United States, 77030 Canada, Alberta Tom Baker Cancer Centre-Calgary; Clinical Research Unit Calgary, Alberta, Canada, T2N 4N2 Canada, Nova Scotia Queen Elizabeth II Health Sciences Centre; Oncology Halifax, Nova Scotia, Canada, B3H 2Y9 Canada, Quebec Centre Hospitalier De L'Universite De Montreal, Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 Germany Uniklinik RWTH Aachen; Med. Klinik IV; Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammz Aachen, Germany, 52074 Campus Virchow-Klinikum Charité Centrum 14; Medizinische Klinik m.S. Hämatologie u. Onkologie Berlin, Germany, 13353 Italy A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia Torino, Piemonte, Italy, 10126 Az. Osp. Di Careggi; Divisione Di Ematologia Firenze, Toscana, Italy, 50135 Less <<
NCT01433445 Idiopathic Myelofibrosis ... More >> Post Essential Thrombocythemia Myelofibrosis Post Polycythemia-Vera Myelofibrosis Less << Phase 1 Active, not recruiting December 31, 2018 France ... More >> Novartis Investigative Site Paris, France, 75010 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Magdeburg, Germany, 39120 Novartis Investigative Site Mainz, Germany, 55131 Ireland Novartis Investigative Site Dublin, Ireland, DUBLIN 8 Novartis Investigative Site Galway, Ireland Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Reggio Calabria, RC, Italy, 89124 Novartis Investigative Site Varese, VA, Italy, 21100 United Kingdom Novartis Investigative Site London, United Kingdom, SE1 9RT Less <<
NCT02494882 Acute Lymphoblastic Leukemia Phase 1 Active, not recruiting June 2019 United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01712659 T Cell Leukemia, Adult ... More >> Leukemia, Adult T-Cell T Cell Leukemia, HTLV I Associated Less << Phase 2 Recruiting November 1, 2021 United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT03558607 Secondary Acute Myelogenous Le... More >>ukemia Evolving From Myeloproliferative Disorder Less << PHASE1|PHASE2 UNKNOWN 2024-08-31 Seoul National University Bund... More >>ang Hospital, Seongnam, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of Less <<
NCT00952289 MPN (Myeloproliferative Neopla... More >>sms) Less << Phase 3 Completed - -
NCT02092324 Atypical Chronic Myeloid Leuke... More >>mia, BCR-ABL1 Negative Chronic Neutrophilic Leukemia Less << Phase 2 Recruiting - United States, California ... More >> Stanford Cancer Institute Palo Alto Recruiting Palo Alto, California, United States, 94304 Contact: Jason Gotlib    650-736-1253    gotlib@stanford.org    Principal Investigator: Jason Gotlib          United States, Georgia Emory University Hospital/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Elliott F. Winton    404-778-4755    ewinton@emory.edu    Principal Investigator: Elliott F. Winton          United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Stephen Oh    314-362-8846    stoh@dom.wustl.edu    Principal Investigator: Stephen Oh          United States, Oregon OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Kim-Hien Dao    503-494-7894    daok@ohsu.edu    Principal Investigator: Kim-Hien Dao          United States, Texas UT Southwestern/Simmons Cancer Center-Dallas Recruiting Dallas, Texas, United States, 75390 Contact: Robert H. Collins    214-648-4155    robert.collins@utsouthwestern.edu    Principal Investigator: Robert H. Collins          M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jorge E. Cortes    713-794-5783    jcortes@mdanderson.org    Principal Investigator: Jorge E. Cortes          United States, Utah Huntsman Cancer Institute/University of Utah Recruiting Salt Lake City, Utah, United States, 84112 Contact: Michael W. Deininger    801-213-5684    michael.deininger@hci.utah.edu    Principal Investigator: Michael W. Deininger Less <<
NCT00952289 - Completed - -
NCT01730755 Erythrocytosis, Familial, 2 NO_LONGER_AVAILABLE - Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT02420717 Leukemia Phase 2 Recruiting July 2023 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT02119663 - Terminated(The safety committe... More >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) Less << - -
NCT02119650 NSCLC (Non-small Cell Lung Car... More >>cinoma) Less << Phase 2 Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << - -
NCT03774082 Graft vs Host Disease Phase 2 Not yet recruiting June 13, 2025 -
NCT02117479 Pancreatic Cancer Phase 3 Terminated(The study was termi... More >>nated early based on the results of the planned interim analysis.) Less << - -
NCT02974647 Lymphoma PHASE2 RECRUITING 2025-11-25 University of Miami, Miami, Fl... More >>orida, United States|Northwestern Medicine (Data collection and specimen analysis), Chicago, Illinois, 60611, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Weill Cornell Medical College, New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, 11553, United States Less <<
NCT02117479 - Terminated(The study was termi... More >>nated early based on the results of the planned interim analysis.) Less << - -
NCT03333187 Bone Marrow Fibrosis Phase 2 Recruiting March 20, 2023 Germany ... More >> Universitätsklinkum Aachen Recruiting Aachen, Germany, 52074 Contact: Edgar Jost, PD Dr.       ejost@ukaachen.de    Principal Investigator: Edgar Jost, PD Dr.          Sub-Investigator: Martina Crysandt, Dr.          HELIOS Klinikum Berlin-Buch Recruiting Berlin, Germany, 13125 Contact: Herrad Baurmann, Dr.       herrad.baurmann@helios-kliniken.de    Principal Investigator: Herrad Baurmann, Dr.          Sub-Investigator: Stephan Fuhrmann, Dr.          Universitätsklinikum Bonn Recruiting Bonn, Germany, 53105 Contact: Dominik Wolf, Prof. Dr.       dominik.wolf@ukb.uni-bonn.de    Principal Investigator: Dominik Wolf, Prof. Dr.          Sub-Investigator: Karin Mayer, Dr.          Universitätsklinikum Düsseldorf Recruiting Düsseldorf, Germany, 40225 Contact: Guido Kobbe, Prof. Dr.       Kobbe@med.uni-duesseldorf.de    Principal Investigator: Guido Kobbe, Prof. Dr.          Sub-Investigator: Thomas Schröder, PD Dr.          Universitätsklinikum Essen Recruiting Essen, Germany, 45147 Contact: Joachim Göthert, Dr.       Joachim.Goethert@uk-essen.de    Principal Investigator: Joachim Göthert, Dr.          Sub-Investigator: Jürgen Novotny, PD Dr.          Klinikum Frankfurt (Oder) GmbH Not yet recruiting Frankfurt (Oder), Germany, 15236 Contact: Michael Kiehl, Prof. Dr.          Contact: Olaf Hopfer, Dr.          Principal Investigator: Olaf Hopfer, Dr.          Sub-Investigator: Georgios Fellas          Universitätsklinkum Halle Recruiting Halle (Saale), Germany, 06120 Contact: Haifa Kathrin Al-Ali, PD Dr.       haifa.al-ali@uk-halle.de    Principal Investigator: Haifa Kathrin Al-Ali, PD Dr.          Sub-Investigator: Nadja Jäkel, Dr.          University Medical Center Hamburg-Eppendorf Recruiting Hamburg, Germany, 20246 Contact: Nicolaus Kroeger, Prof. Dr.    +49-40-7410-55864    n.kroeger@uke.de    Contact: Marion Heinzelmann    +49-40-7410-54188    mheinzel@uke.de    Principal Investigator: Nicolaus Kroeger, Prof. Dr.          Sub-Investigator: Christine Wolschke, Dr.          Universitätsklinikum Jena Recruiting Jena, Germany, 07747 Contact: Inken Hilgendorf, PD Dr.       Inken.Hilgendorf@med.uni-jena.de    Principal Investigator: Inken Hilgendorf, PD Dr.          Sub-Investigator: Nils Winkelmann, Dr.          University Hospital Leipzig Recruiting Leipzig, Germany, 04103 Contact: Dietger Niederwieser, Prof. Dr.       Dietger.Niederwieser@medizin.uni-leipzig.de    Principal Investigator: Dietger Niederwieser, Prof. Dr.          Sub-Investigator: Vladan Vucinic, Dr.          Universitätsmedizin der Johannes Gutenberg-Universität Mainz Recruiting Mainz, Germany, 55131 Contact: Eva Wagner, Dr.       eva.wagner@unimedizin-mainz.de    Principal Investigator: Eva Wagner-Drouet, Dr.          Sub-Investigator: Thomas Kindler, PD Dr.          Universitätsmedizin Mannheim Recruiting Mannheim, Germany, 68167 Contact: Stefan Klein, PD Dr.       Stefan.Klein@medma.uni-heidelberg.de    Principal Investigator: Stefan Klein, PD Dr.          Sub-Investigator: Andreas Reiter, Prof. Dr.          Johannes Wesling Klinikum Minden Recruiting Minden, Germany, 32429 Contact: Martin Griesshammer, Prof. Dr.       martin.griesshammer@muehlenkreiskliniken.de    Principal Investigator: Martin Griesshammer, Prof. Dr.          Sub-Investigator: Hans-Joachim Tischler, Dr.          Universitätsklinikum Münster Recruiting Munster, Germany, 48149 Contact: Matthias Stelljes, Prof. Dr.       Matthias.Stelljes@ukmuenster.de    Principal Investigator: Eva Eßeling, Dr.          Sub-Investigator: Matthias Stelljes, Prof. Dr.          Klinikum Nürnberg Recruiting Nürnberg, Germany, 90419 Contact: Kerstin Schäfer-Eckart, Dr.       Kerstin.Schaefer-Eckart@klinikum-nuernberg.de    Principal Investigator: Kerstin Schäfer-Eckart, Dr.          Sub-Investigator: Knut Wendelin, Dr,          Robert-Bosch-Krankenhaus Stuttgart Recruiting Stuttgart, Germany, 70376 Contact: Martin Kaufmann, Dr.       Martin.Kaufmann@rbk.de    Principal Investigator: Martin Kaufmann, Dr.          Sub-Investigator: Matthias Vöhringer, Dr.          Universitätsmedizin Tübingen Recruiting Tübingen, Germany, 72076 Contact: Wolfgang Bethge, Prof. Dr.       Wolfgang.Bethge@med.uni-tuebingen.de    Principal Investigator: Wolfgang Bethge, Prof. Dr.          Sub-Investigator: Christoph Faul, Dr.          Universitätsklinkum Ulm Recruiting Ulm, Germany, 89081 Contact: Konstanze Döhner, Prof. Dr.       Konstanze.Doehner@uniklinik-ulm.de    Principal Investigator: Konstanze Döhner, Prof. Dr.          Sub-Investigator: Frank Stegelmann, Dr. Less <<
NCT02119663 Pancreatic Cancer Phase 3 Terminated(The safety committe... More >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) Less << - -
NCT03386214 Myelofibroses Phase 1 Recruiting March 31, 2021 United States, Missouri ... More >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Stephen Oh, M.D., Ph.D.    314-747-7960    stoh@wustl.edu    Principal Investigator: Stephen Oh, M.D., Ph.D.          Sub-Investigator: Amy Zhou, M.D. Less <<
NCT01317875 Myelofibrosis PHASE1 COMPLETED 2019-12-31 Winter Park, Florida, 32789, U... More >>nited States|Baltimore, Maryland, 21229, United States|Houston, Texas, 77030, United States|Vienna, Austria|Nanjing, Jiangsu, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Beijing, China|Angers, France|Paris, France|Pierre-Benite, France|Leipzig, Germany|Firenze, Italy|Milano, Italy|Terni, Italy|Rotterdam, Netherlands|Belfast, United Kingdom|London, United Kingdom Less <<
NCT02917096 Primary Myelofibrosis ... More >> Secondary Myelofibrosis Less << Not Applicable Recruiting October 2019 United States, California ... More >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Haris Ali    626-256-4673       Principal Investigator: Haris Ali Less <<
NCT01375140 Myeloproliferative Diseases Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02087059 Primary Myelofibrosis (MF) PHASE3 COMPLETED 2025-04-15 Novartis Investigative Site, N... More >>agoya-city, Aichi, 467-8602, Japan|Novartis Investigative Site, Matsuyama, Ehime, 790-8524, Japan|Novartis Investigative Site, Toon-city, Ehime, 791-0295, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Kurume-city, Fukuoka, 830-0011, Japan|Novartis Investigative Site, Maebashi-city, Gunma, 371-8511, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8543, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8648, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0017, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0047, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, 860-8556, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, 606-8507, Japan|Novartis Investigative Site, Tsu-city, Mie, 514-8507, Japan|Novartis Investigative Site, Sendai-city, Miyagi, 980-8574, Japan|Novartis Investigative Site, Miyazaki-city, Miyazaki, 889-1692, Japan|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Hirakata-city, Osaka, 573-1191, Japan|Novartis Investigative Site, OsakaSayama, Osaka, 589-8511, Japan|Novartis Investigative Site, Suita-city, Osaka, 565-0871, Japan|Novartis Investigative Site, Shimotsuke-city, Tochigi, 329-0498, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8431, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8519, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8603, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8677, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160-0023, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 162-8666, Japan|Novartis Investigative Site, Chuo-city, Yamanashi, 409-3898, Japan|Novartis Investigative Site, Akita, 010-8543, Japan|Novartis Investigative Site, Gifu, 501-1194, Japan Less <<
NCT02087059 Primary Myelofibrosis (MF) PHASE3 COMPLETED 2025-04-15 Novartis Investigative Site, N... More >>agoya-city, Aichi, 467-8602, Japan|Novartis Investigative Site, Matsuyama, Ehime, 790-8524, Japan|Novartis Investigative Site, Toon-city, Ehime, 791-0295, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Kurume-city, Fukuoka, 830-0011, Japan|Novartis Investigative Site, Maebashi-city, Gunma, 371-8511, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8543, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8648, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0017, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0047, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, 860-8556, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, 606-8507, Japan|Novartis Investigative Site, Tsu-city, Mie, 514-8507, Japan|Novartis Investigative Site, Sendai-city, Miyagi, 980-8574, Japan|Novartis Investigative Site, Miyazaki-city, Miyazaki, 889-1692, Japan|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Hirakata-city, Osaka, 573-1191, Japan|Novartis Investigative Site, OsakaSayama, Osaka, 589-8511, Japan|Novartis Investigative Site, Suita-city, Osaka, 565-0871, Japan|Novartis Investigative Site, Shimotsuke-city, Tochigi, 329-0498, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8431, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8519, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8603, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8677, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160-0023, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 162-8666, Japan|Novartis Investigative Site, Chuo-city, Yamanashi, 409-3898, Japan|Novartis Investigative Site, Akita, 010-8543, Japan|Novartis Investigative Site, Gifu, 501-1194, Japan Less <<
NCT03373877 Myelofibrosis ... More >> Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Less << Phase 1 Recruiting December 2019 United States, Connecticut ... More >> Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06511 Contact: Kris Awerkamp, BSN RN CCRP    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Nikolai Podoltsev, MD PhD          United States, Louisiana Ochsner Clinic Foundation Recruiting New Orleans, Louisiana, United States, 70121 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Laura Finn, MD          United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Moshe Talpaz, MD          Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Jay Yang, MD          United States, Nebraska University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States, 68198 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Krishna Gundabolu, MD          United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Kris Awerkamp, BSN RN CCRP    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Murat Arcasoy, MD          United States, Ohio Cleveland Clinic - Taussig Cancer Institute Recruiting Cleveland, Ohio, United States, 44195 Contact: Kris Awerkamp, BSN RN CCRP    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Moshe Talpaz, MD          United States, Pennsylvania Abramson Cancer Center - University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Elizabeth Hexner, MD          United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Naveen Pemmaraju, MD          Mays Cancer Center UT Health San Antonio Recruiting San Antonio, Texas, United States, 78229-3900 Contact: Kris Awerkamp, BSN, RN, CCRP    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Ruben A. Mesa, MD, FACP Less <<
NCT02913261 Corticosteroid Refractory Acut... More >>e Graft vs Host Disease Less << Phase 3 Recruiting March 8, 2021 -
NCT00639002 Multiple Myeloma Phase 2 Completed - United States, California ... More >> Highland, California, United States, 92346 United States, Florida Boynton Beach, Florida, United States, 33435 United States, New York New York, New York, United States, 10011 Less <<
NCT02475655 HIV Infections PHASE2 COMPLETED 2018-04-04 Alabama CRS, Birmingham, Alaba... More >>ma, 35294, United States|UCLA CARE Center CRS, Los Angeles, California, 90035, United States|UCSD Antiviral Research Center CRS, San Diego, California, 92103, United States|Ucsf Hiv/Aids Crs, San Francisco, California, 94110, United States|Northwestern University CRS, Chicago, Illinois, 60611, United States|Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, 63110-1010, United States|Weill Cornell Chelsea CRS, New York, New York, 10010, United States|Weill Cornell Uptown CRS, New York, New York, 10065, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, 14642, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, 45219, United States|Case Clinical Research Site, Cleveland, Ohio, 44106, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, 19104, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, 02906, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, 37204, United States Less <<
NCT00509899 Myelofibrosis|Polycythemia Ver... More >>a|Thrombocytosis Less << PHASE1|PHASE2 COMPLETED 2025-02-17 Rochester, Minnesota, United S... More >>tates|Houston, Texas, United States Less <<
NCT02119676 CRC (Colorectal Cancer) Phase 2 Terminated(Substudy 1 was term... More >>inated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.) Less << - -
NCT02119676 - Terminated(Substudy 1 was term... More >>inated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.) Less << - -
NCT02038036 Polycythemia Vera Phase 3 Active, not recruiting April 8, 2020 -
NCT01644110 Primary Myelofibrosis ... More >> Secondary Myelofibrosis PMF SMF Post-PV MF Post-ET MF Less << Phase 1 Phase 2 Recruiting May 2022 Germany ... More >> University of Ulm Recruiting Ulm, Germany, 89081 Contact: Konstanze Doehner, MD       konstanze.doehner@uniklinik-ulm.de    Principal Investigator: konstanze Doehner, Md Less <<
NCT00509899 Myelofibrosis|Polycythemia Ver... More >>a|Thrombocytosis Less << PHASE1|PHASE2 COMPLETED 2025-02-17 Rochester, Minnesota, United S... More >>tates|Houston, Texas, United States Less <<
NCT02997280 Graft Vs Host Disease Phase 2 Recruiting June 2019 Russian Federation ... More >> First Pavlov State Medical University of St. Petersburg Recruiting Saint-Petersburg, Russian Federation, 197089 Contact: Ivan S. Moiseev, PhD    +79217961951    moisiv@mail.ru    Contact: Boris V. Afanasyev, Prof    +78122334551    coordinatorbmt@gmail.com Less <<
NCT00639002 - Completed - -
NCT00726232 Myeloproliferative Neoplasm (M... More >>PN) Less << PHASE2 TERMINATED 2018-08-20 Houston, Texas, 77030, United ... More >>States|Bergamo, Italy|Firenze, Italy|Pavia, Italy Less <<
NCT02120417 Breast Cancer Phase 2 Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << - -
NCT02292446 Polycythemia Vera PHASE3 COMPLETED 2017-12-29 Novartis Investigative Site, L... More >>inz, A-4010, Austria|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, Wels, A 4600, Austria|Novartis Investigative Site, Antwerp, 2060, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Bruxelles, 1070, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Liege, 4000, Belgium|Novartis Investigative Site, Yvoir, 5530, Belgium|Novartis Investigative Site, Pleven, 5800, Bulgaria|Novartis Investigative Site, Plovdiv, 4002, Bulgaria|Novartis Investigative Site, Sofia, 1413, Bulgaria|Novartis Investigative Site, Sofia, 1431, Bulgaria|Novartis Investigative Site, Vancouver, British Columbia, V5Z 1M9, Canada|Novartis Investigative Site, Hamilton, Ontario, L8V 5C2, Canada|Novartis Investigative Site, Vina del Mar, Valparaiso, 2540364, Chile|Novartis Investigative Site, Santiago, 8420383, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Bayonne, Bayonne Cedex, 64109, France|Novartis Investigative Site, Le Mans, Cedex 09, 72037, France|Novartis Investigative Site, Angers Cedex 1, 49033, France|Novartis Investigative Site, Avignon cedex 9, 84902, France|Novartis Investigative Site, Bordeaux, 33076, France|Novartis Investigative Site, Chambéry Cedex, 73011, France|Novartis Investigative Site, Marseille, 13273, France|Novartis Investigative Site, Meaux cedex, 77104, France|Novartis Investigative Site, Metz, 57000, France|Novartis Investigative Site, Mulhouse cedex, 68070, France|Novartis Investigative Site, Nice Cedex, 06202, France|Novartis Investigative Site, Paris, 75010, France|Novartis Investigative Site, Perpignan, 66046, France|Novartis Investigative Site, Pringy cedex, 74374, France|Novartis Investigative Site, Toulouse Cedex 9, 31059, France|Novartis Investigative Site, Vandoeuvre Les Nancy, 54511, France|Novartis Investigative Site, Villejuif Cedex, 94805, France|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, 68305, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Augsburg, 86150, Germany|Novartis Investigative Site, Bad Soden, 65812, Germany|Novartis Investigative Site, Berlin, 13357, Germany|Novartis Investigative Site, Bottrop, 46236, Germany|Novartis Investigative Site, Eisenach, 99817, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Frankfurt, 60389, Germany|Novartis Investigative Site, Frankfurt, 60596, Germany|Novartis Investigative Site, Friedrichshafen, 88045, Germany|Novartis Investigative Site, Hamburg, 22081, Germany|Novartis Investigative Site, Hamm, 59063, Germany|Novartis Investigative Site, Heidelberg, 69115, Germany|Novartis Investigative Site, Heilbronn, 74072, Germany|Novartis Investigative Site, Koblenz, 56068, Germany|Novartis Investigative Site, Mutlangen, 73557, Germany|Novartis Investigative Site, Stuttgart, 70376, Germany|Novartis Investigative Site, Wuerzburg, 97080, Germany|Novartis Investigative Site, Monterrey, Nuevo Leon, 64000, Mexico|Novartis Investigative Site, Fredrikstad, NO-1603, Norway|Novartis Investigative Site, Tromso, 9038, Norway|Novartis Investigative Site, Lisboa, 1099 023, Portugal|Novartis Investigative Site, Lisboa, 1749-035, Portugal|Novartis Investigative Site, Lulea, SE 971 80, Sweden|Novartis Investigative Site, Uddevalla, 451 80, Sweden|Novartis Investigative Site, Khon Kaen, THA, 40002, Thailand|Novartis Investigative Site, Bangkok, 10400, Thailand|Novartis Investigative Site, Bangkok, 10700, Thailand|Novartis Investigative Site, Chiang Mai, 50200, Thailand Less <<
NCT01348490 MPN (Myeloproliferative Neopla... More >>sms) Less << PHASE2 COMPLETED 2018-12-19 Birmingham, Alabama, United St... More >>ates|Beverly Hills, California, United States|Burbank, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Pomona, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Orange City, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Southfield, Michigan, United States|Saint Louis, Missouri, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|Somerville, New Jersey, United States|New York, New York, United States|Durham, North Carolina, United States|Hickory, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Danville, Pennsylvania, United States|Hershey, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States Less <<
NCT02598297 Early Myelofibrosis With High ... More >>Molecular Risk Mutations Less << Phase 3 Completed - -
NCT02257138 Blasts More Than 20 Percent of... More >> Bone Marrow Nucleated Cells Blasts More Than 20 Percent of Peripheral Blood White Cells Myelodysplastic/Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Less << Phase 1 Phase 2 Recruiting February 1, 2019 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Farhad Ravandi-Kashani    713-745-0394       Principal Investigator: Farhad Ravandi-Kashani Less <<
NCT02396628 Graft vs Host Disease Phase 2 Recruiting March 2023 Germany ... More >> Charité - Universitätsmedizin Berlin Recruiting Berlin, Germany, 13353 Principal Investigator: Igor Blau, PD Dr.          Sub-Investigator: Il-Kang Na, PD Dr.          Sub-Investigator: Giang Lam Vuong, Dr.          Universitätsklinikum Bonn Recruiting Bonn, Germany, 53105 Principal Investigator: Dominik Wolf, Prof.          Sub-Investigator: Karin Mayer, Dr.          Universitätsklinikum Dresden Recruiting Dresden, Germany, 01307 Principal Investigator: Friedrich Stölzel, Dr.          Sub-Investigator: Rainer Ordemann, Prof.          University Medical Center Recruiting Freiburg, Germany, 79106 Contact: Nikolas von Bubnoff, Professor       nikolas.bubnoff@uniklinik-freiburg.de    Principal Investigator: Nikolas von Bubnoff, Professor          Sub-Investigator: Robert Zeiser, Professor          Universitätsklinikum Hamburg Eppendorf Recruiting Hamburg, Germany, 20246 Principal Investigator: Francis Ayuk, PD Dr.          Sub-Investigator: Dietlinde Janson, Dr.          Universitätsklinikum Heidelberg Recruiting Heidelberg, Germany, 69120 Principal Investigator: Peter Dreger, Prof.          Sub-Investigator: Thomas Luft, PD Dr.          Universitätsklinikum des Saarlandes Recruiting Homburg, Germany, 66421 Contact: Jörg T. Bittenbring, Dr.          Principal Investigator: Jörg T. Bittenbring, Dr.          Sub-Investigator: Niels Murawski, PD Dr.          Universitätsklinikum Köln Recruiting Köln, Germany, 50937 Contact: Udo Holtick, Dr.          Principal Investigator: Udo Holtick, Dr.          Sub-Investigator: Christof Scheid, Prof.          Sub-Investigator: Marco Herling, Dr.          Universitätsklinikum Marburg Recruiting Marburg, Germany, 35043 Contact: Andreas Burchert, Prof.          Principal Investigator: Andreas Burchert, Prof.          Sub-Investigator: Kristina Sohlbach, Dr.          Universitätsklinikum München TU rechts der Isar Recruiting München, Germany, 81675 Principal Investigator: Mareike Verbeek, Dr.          Sub-Investigator: Sandra Grass, Dr.          Universitätsklinikum Würzburg Recruiting Würzburg, Germany, 97080 Principal Investigator: Götz Grigoleit, Dr.          Sub-Investigator: Sabrina Kraus, Dr. Less <<
NCT03144687 MPN (Myeloproliferative Neopla... More >>sms) Less << Phase 2 Recruiting March 2019 United States, Arizona ... More >> Arizona Oncology Associates Recruiting Tempe, Arizona, United States, 85284 Contact: Study Coordinator    480-256-1664       Principal Investigator: Kasra Karamlou          United States, California UC Irvine Medical Center Recruiting Orange, California, United States, 92868 Contact: Study Coordinator    714-456-5408       Principal Investigator: Angela Fleischman, MD          United States, Colorado Anschutz Cancer Pavilion - University Of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Study Coordinator    720-848-2587       Principal Investigator: Brandon McMahon          United States, Connecticut Norwalk Hospital Recruiting Norwalk, Connecticut, United States, 06856 Contact: Study Coordinator    203-852-2996       Principal Investigator: Richard Frank          United States, District of Columbia Georgetown University Hospital Not yet recruiting Washington, District of Columbia, United States, 20007 Contact: Study Coordinator    202-687-0116       Principal Investigator: Craig Kessler          United States, Indiana Parkview Research Center Recruiting Fort Wayne, Indiana, United States, 46845 Contact: Study Coordinator    260-425-6831       Principal Investigator: Robert Manges          United States, Maryland University Of Maryland - Greenebaum Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Study Coordinator    410-328-6635       Principal Investigator: Duong          United States, Michigan University of Michigan Health System Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Study Coordinator    734-936-3879       Principal Investigator: Moshe Talpaz, MD          Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Study Coordinator    313-576-9758       Principal Investigator: Jay Yang          Providence Cancer Center Recruiting Southfield, Michigan, United States, 48075 Contact: Study Coordinator    248-849-5332       Principal Investigator: Howard Terebelo          United States, New Mexico University Of New Mexico Cancer Center Recruiting Albuquerque, New Mexico, United States, 87102 Contact: Study Coordinator    505-925-0379       Principal Investigator: Arana Yi          United States, New York Weill Cornell Medical Centers Not yet recruiting New York, New York, United States, 10065 Contact: Study Coordinator    212-746-2389       Principal Investigator: Ellen Ritchie          New York Medical College Not yet recruiting Valhalla, New York, United States, 10595 Contact: Study Coordinator    914-493-8375       Principal Investigator: Karen Seiter          United States, North Carolina Duke University Medical Center Not yet recruiting Durham, North Carolina, United States, 27710 Contact: Study Coordinator    919-681-4769       Principal Investigator: Murat Arcasoy          United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Study Coordinator    216-444-9464       Principal Investigator: Aaron Gerds, MD          United States, Oregon Willamette Valley Cancer Institute Recruiting Eugene, Oregon, United States, 97401 Contact: Study Coordinator    281-863-4631       Principal Investigator: Jeff Sharman, MD          United States, Texas Texas Oncology San Antonio Recruiting San Antonio, Texas, United States, 78240 Contact: Study Coordinator    210-595-5680       Principal Investigator: Roger Lyons          Texas Oncology - Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Study Coordinator    903-579-9800       Principal Investigator: Habte Yimer          United States, Virginia University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 Contact: Study Coordinator    434-982-3927       Principal Investigator: Michael Keng, MD Less <<
NCT00638378 Prostate Cancer PHASE2 TERMINATED 2025-01-09 Highland, California, United S... More >>tates|Montebello, California, United States|Mountain View, California, United States|Galesburg, Illinois, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Grand Rapids, Michigan, United States|Jefferson City, Missouri, United States|Great Falls, Montana, 59405, United States|Cherry Hill, New Jersey, United States|Staten Island, New York, United States|Bismarck, North Dakota, United States|Bethlehem, Pennsylvania, United States|Sumter, South Carolina, United States|Lacey, Washington, United States Less <<
NCT02131584 Chronic Lymphocytic Leukemia ... More >> Fatigue Less << Phase 2 Active, not recruiting September 30, 2022 United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01431209 Recurrent Diffuse Large B-Cell... More >> Lymphoma Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Less << Phase 2 Active, not recruiting December 2019 United States, Maryland ... More >> National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 Less <<
NCT02436135 Myelofibrosis Phase 1 Completed - United States, California ... More >> Stanford Hospital and Clinics Stanford, California, United States, 94305 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Less <<
NCT02955940 Pancreatic Cancer ... More >> Colorectal Cancer (CRC) Breast Cancer Lung Cancer Less << Phase 2 Enrolling by invitation November 2019 United States, Kentucky ... More >> University of Louisville Louisville, Kentucky, United States, 40202 United States, New York New York Oncology Hematology PC Hudson, New York, United States, 12534 United States, Texas U of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02076191 Myeloproliferative Neoplasms Phase 1 Phase 2 Active, not recruiting December 2018 United States, Missouri ... More >> Washington University of St. Louis Saint Louis, Missouri, United States, 63110 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Columbia University Medical Center New York, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Wake Forest University Baptist Medical Center Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Taussig Cancer Center Institute Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00638378 Prostate Cancer PHASE2 TERMINATED 2025-01-09 Highland, California, United S... More >>tates|Montebello, California, United States|Mountain View, California, United States|Galesburg, Illinois, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Grand Rapids, Michigan, United States|Jefferson City, Missouri, United States|Great Falls, Montana, 59405, United States|Cherry Hill, New Jersey, United States|Staten Island, New York, United States|Bismarck, North Dakota, United States|Bethlehem, Pennsylvania, United States|Sumter, South Carolina, United States|Lacey, Washington, United States Less <<
NCT03701698 Acute GVHD Phase 2 Not yet recruiting October 31, 2021 China, Shanghai ... More >> Shanghai General Hospital Active, not recruiting Shanghai, Shanghai, China, 200080 Less <<
NCT01562873 Breast Cancer PHASE2 TERMINATED 2025-06-16 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT01776723 Myelomonocytic Leukemia PHASE1|PHASE2 COMPLETED 2022-05-10 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Weill Medical College of Cornell, New York, New York, 10021, United States|Cleveland Clinic, Cleveland, Ohio, 44106, United States Less <<
NCT01562873 Breast Cancer PHASE2 TERMINATED 2025-06-16 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT02400463 Hemophagocytic Syndrome (HPS) PHASE2 COMPLETED 2020-01-07 University of Michigan Compreh... More >>ensive Cancer Center, Ann Arbor, Michigan, 48109, United States Less <<
NCT02966353 Primary Myelofibrosis ... More >> Post-Polycythemia Vera-Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis Less << Phase 2 Active, not recruiting February 15, 2019 Austria ... More >> Novartis Investigative Site Vienna, Austria, A-1090 Belgium Novartis Investigative Site Antwerpen, Belgium, 2060 Novartis Investigative Site Leuven, Belgium, 3000 Bulgaria Novartis Investigative Site Sofia, Bulgaria, 1413 Novartis Investigative Site Sofia, Bulgaria, 1756 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1M9 Germany Novartis Investigative Site Halle/S., Germany, 06120 Greece Novartis Investigative Site Thessaloniki, GR, Greece, 570 10 Novartis Investigative Site Athens, Greece, 11527 Italy Novartis Investigative Site Bologna, BO, Italy, 40138 Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Palermo, PA, Italy, 90127 Japan Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8431 Russian Federation Novartis Investigative Site Moscow, Russian Federation, 125167 Novartis Investigative Site Moscow, Russian Federation, 129110 Novartis Investigative Site Petrozavodsk, Russian Federation, 185019 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Alicante, Comunidad Valenciana, Spain, 03010 Novartis Investigative Site Santiago de Compostela, Galicia, Spain, 15706 Turkey Novartis Investigative Site Istanbul, Turkey, 34093 Novartis Investigative Site Kocaeli, Turkey, 41380 Less <<
NCT02091752 Primary Myelofibrosis PHASE2 TERMINATED 2025-02-15 Novartis Investigative Site, L... More >>eipzig, 04103, Germany|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Madrid, 28034, Spain Less <<
NCT02253277 Chronic Myeloid Leukemia Phase 1 Phase 2 Completed - Germany ... More >> Novartis Investigative Site Berlin, Germany, 13353 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Jena, Germany, 07740 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site Mannheim, Germany, 68169 Less <<
NCT02091752 Primary Myelofibrosis PHASE2 TERMINATED 2025-02-15 Novartis Investigative Site, L... More >>eipzig, 04103, Germany|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Madrid, 28034, Spain Less <<
NCT01251965 Leukemia PHASE1|PHASE2 TERMINATED 2025-07-12 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00726232 Myeloproliferative Neoplasm (M... More >>PN) Less << PHASE2 TERMINATED 2018-08-20 Houston, Texas, 77030, United ... More >>States|Bergamo, Italy|Firenze, Italy|Pavia, Italy Less <<
NCT01702064 Chronic Phase Chronic Myeloid ... More >>Leukemia Less << Phase 1 Active, not recruiting March 2019 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT02876302 Inflammatory Breast Cancer (IB... More >>C) Less << Phase 2 Recruiting February 2024 United States, Maryland ... More >> Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Vered Stearns, MD       vstearn1@jhmi.edu    Johns Hopkins at Green Spring Station Recruiting Lutherville, Maryland, United States, 21093 Contact: Vered Stearns, MD       Vstearn1@jhmi.edu    United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Beth Overmoyer, MD, FACP    617-632-4056    bovermoyer@partners.org    Principal Investigator: Beth Overmoyer, MD, FACP          United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Catherine Van Poznak, MD       cvanpoz@med.umich.edu    United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Tufia Haddad, MD       Haddad.Tufia@mayo.edu    United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Jeremy Force, MD       Jeremy.force@duke.edu    United States, Pennsylvania University of Pennslyvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Amy Clark, MD       Clarkamy@mail.upenn.edu    United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Naoto Ueno, MD       Nueno@mdanderson.org Less <<
NCT01340651 Myelofibrosis PHASE2 COMPLETED 2025-07-12 Scottsdale, Arizona, United St... More >>ates|Winter Park, Florida, United States|Houston, Texas, TX, United States Less <<
NCT01340651 Myelofibrosis PHASE2 COMPLETED 2025-07-12 Scottsdale, Arizona, United St... More >>ates|Winter Park, Florida, United States|Houston, Texas, TX, United States Less <<
NCT02155465 Lung Cancer Phase 1 Phase 2 Completed - United States, New Jersey ... More >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering West Harrison Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States Memoral Sloan Kettering Cancer Center at Phelps Sleepy Hollow, New York, United States, 10591 Less <<
NCT01445769 Primary Myelofibrosis|Post-Pol... More >>ycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis Less << PHASE2 COMPLETED 2025-04-13 Highland, California, United S... More >>tates|La Jolla, California, United States|Los Angeles, California, United States|Jacksonville, Florida, United States|Orange City, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Southfield, Michigan, United States|Morristown, New Jersey, United States|Armonk, New York, United States|Hickory, North Carolina, United States|Canton, Ohio, United States|Hazleton, Pennsylvania, United States|Hershey, Pennsylvania, United States|Charleston, South Carolina, United States|Sioux Falls, South Dakota, United States|San Antonio, Texas, United States Less <<
NCT01445769 Primary Myelofibrosis|Post-Pol... More >>ycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis Less << PHASE2 COMPLETED 2025-04-13 Highland, California, United S... More >>tates|La Jolla, California, United States|Los Angeles, California, United States|Jacksonville, Florida, United States|Orange City, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Southfield, Michigan, United States|Morristown, New Jersey, United States|Armonk, New York, United States|Hickory, North Carolina, United States|Canton, Ohio, United States|Hazleton, Pennsylvania, United States|Hershey, Pennsylvania, United States|Charleston, South Carolina, United States|Sioux Falls, South Dakota, United States|San Antonio, Texas, United States Less <<
NCT03610971 Chronic Phase Chronic Myeloid ... More >>Leukemia Chronic Myeloid Leukemia, Chronic Phase Less << Phase 2 Not yet recruiting January 2022 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting Tampa, Florida, United States, 33612 Contact: Anthony McLaughlin    813-745-5941    anthony.mclaughlin@moffitt.org    Contact: Kendra Sweet, M.D.    813-745-8986    kendra.sweet@moffitt.org    Principal Investigator: Kendra Sweet, M.D. Less <<
NCT01693601 Myelofibrosis Phase 1 Phase 2 Active, not recruiting February 2019 United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less <<
NCT02015208 Chronic Lymphocytic Leukemia PHASE1|PHASE2 COMPLETED 2025-07-15 Sunnybrook Odette Cancer Cente... More >>r, Toronto, Ontario, M4N3M5, Canada Less <<
NCT03571321 Acute Lymphoblastic Leukemia ... More >> ALL, Childhood ALL Less << Phase 1 Not yet recruiting September 5, 2024 United States, Illinois ... More >> University of Chicago Medical Center Not yet recruiting Chicago, Illinois, United States, 60637 Contact: Howie Weiner    773-702-2084    hweiner@medicine.bsd.uchicago.edu    Contact: Peggy Green, RN    (773) 702-0267    mgreen@medicine.bsd.uchicago.edu    Principal Investigator: Emily Currant, MD Less <<
NCT03069326 Myelofibrosis Phase 2 Recruiting February 2019 United States, New Jersey ... More >> Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Raajit Rampal, MD, PhD    212-639-2194       United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Raajit Rampa, MD, PhD    212-639-2194       Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Raajit Rampal, MD, PhD    212-639-2194       Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Raajit Rampal, MD, PhD    212-639-2194       Contact: Ellin Berman, MD    212-639-7762       Principal Investigator: Raajit Rampal, MD, PhD          Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Raajit Rampal, MD, PhD    212-639-2194       United States, Texas Md Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Prithvira Bose, MD    713-792-7747       Principal Investigator: Prithvira Bose, MD Less <<
NCT01950780 Alopecia Areata PHASE2 COMPLETED 2025-04-16 Columbia University Medical Ce... More >>nter, Department of Dermatology, New York, New York, 10032, United States Less <<
NCT02613598 Hodgkin's Lymphoma ... More >> Lymphoma, Non-Hodgkin Less << Phase 1 Recruiting October 2021 United States, Michigan ... More >> University of Michgan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48187 Contact: Tycel Phillips, M.D.    734-232-2883    tycelp@umich.edu    Principal Investigator: Tycel Phillips, M.D. Less <<
NCT02066532 Metastatic Breast Cancer ... More >> Breast Carcinoma HER-2 Positive Breast Cancer Less << Phase 1 Phase 2 Recruiting December 2018 United States, New York ... More >> Mount Sinai Medical Center Recruiting New York, New York, United States, 10029 Contact: Amy Tiersten, MD    212-241-2299    amy.tiersten@mssm.edu    Principal Investigator: Amy Tiersten, MD          Columbia University Medical Center Recruiting New York, New York, United States, 10032 Contact: Kevin Kalinsky, MD, MS    212-305-1945    KK2693@cumc.columbia.edu    Contact: Dan Otap, CCRP    212-342-3970    DO2267@cumc.columbia.edu    Principal Investigator: Kevin Kalinsky, MD, MS          New York Hospital-Weill Cornell Medical Center Recruiting New York, New York, United States, 10065 Contact: Tessa Cigler, MD    212-821-0644    elc2007@med.cornell.edu    Principal Investigator: Tessa Cigler, MD          Montefiore Medical Center Recruiting New York, New York, United States, 10461 Contact: Della Makower, MD    718-405-8529    dmakower@montefiore.org    Principal Investigator: Della Makower, MD Less <<
NCT03674047 Other Cancer Phase 2 Not yet recruiting March 31, 2023 United States, Massachusetts ... More >> Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02214 Contact: Zachariah DeFilipp, MD    617-724-4000    zdefilipp@mgh.harvard.edu    Principal Investigator: Zachariah DeFilipp, MD Less <<
NCT03491215 Acute Graft Versus Host Diseas... More >>e Less << PHASE1|PHASE2 COMPLETED 2023-02-02 Novartis Investigative Site, G... More >>ent, 9000, Belgium|Novartis Investigative Site, Laeken, 1020, Belgium|Novartis Investigative Site, Montreal, Quebec, H3T 1C5, Canada|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Lille, 59000, France|Novartis Investigative Site, Nantes Cedex 01, 44093, France|Novartis Investigative Site, Paris 15, 75015, France|Novartis Investigative Site, Paris, 75019, France|Novartis Investigative Site, Rennes, 35022, France|Novartis Investigative Site, Vandoeuvre Les Nancy, 54511, France|Novartis Investigative Site, Genova, GE, 16147, Italy|Novartis Investigative Site, Roma, RM, 00165, Italy|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan|Novartis Investigative Site, Saitama, 330 8777, Japan|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Madrid, 28009, Spain|Novartis Investigative Site, Madrid, 28046, Spain Less <<
NCT03222609 Myelofibrosis (MF) Phase 2 Recruiting June 11, 2021 United States, Alabama ... More >> UAB Comprehensive Cancer Cente /ID# 165464 Recruiting Birmingham, Alabama, United States, 35217 United States, California Ucsd /Id# 164084 Recruiting La Jolla, California, United States, 92037 Usc /Id# 164095 Recruiting Los Angeles, California, United States, 90033 United States, Florida Mayo Clinic /ID# 164201 Recruiting Jacksonville, Florida, United States, 32224 Moffitt Cancer Center /ID# 164082 Recruiting Tampa, Florida, United States, 33612 United States, Illinois University of Chicago /ID# 164115 Recruiting Chicago, Illinois, United States, 60637 United States, Indiana Indiana Blood & Marrow Transpl /ID# 165075 Recruiting Indianapolis, Indiana, United States, 46237 United States, Massachusetts Dana-Farber Cancer Institute /ID# 162675 Recruiting Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital /ID# 162682 Recruiting Detroit, Michigan, United States, 48202 United States, New York Weill Cornell Medical College /ID# 162679 Recruiting New York, New York, United States, 10021 United States, Texas MD Anderson Cancer Center /ID# 162683 Recruiting Houston, Texas, United States, 77030 UT Health Cancer Center /ID# 164094 Recruiting San Antonio, Texas, United States, 78229 United States, Utah University of Utah /ID# 164116 Recruiting Salt Lake City, Utah, United States, 84112-5500 United Kingdom Guy's and St Thomas' NHS Found /ID# 164110 Recruiting London, London, City Of, United Kingdom, SE1 9RT Christie NHS Foundation Trust /ID# 164111 Recruiting Manchester, United Kingdom, M20 4BX Less <<
NCT02469974 Myelofibrosis ... More >> MF Less << Not Applicable Withdrawn(no enrollments) - -
NCT03613428 Acute T Cell Leukemia Phase 1 Phase 2 Not yet recruiting March 30, 2021 -
NCT02723994 Leukemia Phase 2 Recruiting May 2024 -
NCT03745651 Atopic Dermatitis Phase 3 Recruiting September 2020 United States, Florida ... More >> San Marcus Research Clinic Inc Recruiting Miami, Florida, United States, 33015 Well Pharma Medical Research Corporation Not yet recruiting Miami, Florida, United States, 33143 Forward Clinical Trials Inc Not yet recruiting Tampa, Florida, United States, 33624 United States, Georgia Clinical Research Atlanta Not yet recruiting Stockbridge, Georgia, United States, 30281 United States, Kentucky Derm Research LLC Not yet recruiting Louisville, Kentucky, United States, 40217 Dermatology Specialists PSC Not yet recruiting Louisville, Kentucky, United States, 40241 United States, New Hampshire ActivMed Practices & Research Inc Not yet recruiting Portsmouth, New Hampshire, United States, 03801 United States, New Jersey Hassman Research Institute Not yet recruiting Berlin, New Jersey, United States, 08009 United States, Ohio Synexus Clinical Research US, Inc. - Cincinnati Not yet recruiting Cincinnati, Ohio, United States, 45236 United States, Pennsylvania Paddington Testing Company Inc Not yet recruiting Philadelphia, Pennsylvania, United States, 19103 United States, South Carolina Synexus Clinical Research US, Inc. - Anderson Not yet recruiting Anderson, South Carolina, United States, 29621 United States, Texas Clinical Trials of Texas Incorporated Not yet recruiting San Antonio, Texas, United States, 78229 Center for Clinical Studies Not yet recruiting Webster, Texas, United States, 77598 United States, Virginia Clinical Research Partners LLC Not yet recruiting Henrico, Virginia, United States, 23233 United States, Washington Dermatology Specialists of Spokane Not yet recruiting Spokane, Washington, United States, 99204 Less <<
NCT03112603 Graft-versus-host Disease (GVH... More >>D) Less << Phase 3 Recruiting January 2022 -
NCT03153982 Head and Neck Squamous Cell Ca... More >>rcinoma Less << PHASE2 TERMINATED 2023-10-18 University of Arizona Cancer C... More >>enter, Tucson, Arizona, 85724, United States|University of California, San Francisco, San Francisco, California, 94143, United States Less <<
NCT02973711 Leukemia, Chronic Myeloid Phase 1 Phase 2 Recruiting April 2021 United States, Michigan ... More >> The University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Patrick Burke, M.D.    734-647-8921    pwburke@umich.edu    Principal Investigator: Patrick Burke, M.D.          United States, North Carolina Wake Forest University Health Sciences Not yet recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Rupali Bhave, M.D.    336-713-0864    rbhave@wakehealth.edu    Contact: Megan Brown-Farmer    336-713-6913    mebrown@wakehealth.edu Less <<
NCT02953678 Graft-versus-host Disease (GVH... More >>D) Less << Phase 2 Active, not recruiting June 2020 -
NCT03745638 Atopic Dermatitis Phase 3 Recruiting September 2020 -
NCT03147742 Graft-versus-host Disease (GVH... More >>D) Less << APPROVED_FOR_MARKETING - Mayo Clinic Arizona, Phoenix, ... More >>Arizona, 85054, United States|Cancer Transplant Institute at HonorHealth, Scottsdale, Arizona, 85258, United States|City of Hope Medical Center, Duarte, California, 91010, United States|Scripps Clinic, La Jolla, California, 92037, United States|Colorado Blood Cancer Institute, Denver, Colorado, 80218, United States|Nicklaus Children's Hospital, Miami, Florida, 33155, United States|Blood & Marrow Transplant Center, Orlando, Florida, 32804, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|University of Illinois Chicago, Chicago, Illinois, 60612, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, 46237, United States|Cancer Center of Kansas, Wichita, Kansas, 67214, United States|Massachusetts General Hospital, Boston, Massachusetts, 02214, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109-5271, United States|Spectrum Health, Grand Rapids, Michigan, 49503, United States|Mayo Clinic Minnesota, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Rutgers Cancer Institute, New Brunswick, New Jersey, 08903, United States|New Mexico Cancer Center, Albuquerque, New Mexico, 87109, United States|Weill Cornell Medical College, New York, New York, 10021, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Ohio State University, Columbus, Ohio, 43210, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, 17325, United States|Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, 15224, United States|Greenville Health System Cancer Institute, Greenville, South Carolina, 29615, United States|Avera Research Institute, Sioux Falls, South Dakota, 57105, United States|Texas Oncology, Dallas, Texas, 75246, United States|Houston Methodist, Houston, Texas, 77030, United States|Methodist Hospital, San Antonio, Texas, 78229, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109-1024, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<
NCT03110822 Multiple Myeloma Phase 1 Recruiting May 2020 United States, California ... More >> Comprehensive Blood and Cancer Center Recruiting Bakersfield, California, United States, 93309-0633 Contact: Nicole Henry    661-862-8548    nhenry@cbccusa.com    Principal Investigator: Ravindranath Patel, MD          California Cancer Associates for Research & Excellence (cCARE) Recruiting Encinitas, California, United States, 92024 Contact: Daniela Slavin, PhD    760-452-3909    dslavin@ccare.com    Principal Investigator: Alberto Bessudo, MD          Robert A. Moss, M.D., F.A.C.P., Inc. Recruiting Fountain Valley, California, United States, 92708 Contact: Helen Tam    714-641-1128    helen.tam@sbcglobal.net    Principal Investigator: Robert A Moss, MD          Pacific Cancer Care Recruiting Monterey, California, United States, 93940 Contact: Dorothy Tenney    831-375-4105    dtenney@pacificcancercare.com    Principal Investigator: Laura Stampleman, MD          Sansum Clinic- Ridley-Tree Cancer Center Recruiting Santa Barbara, California, United States, 93105 Contact: Heidi Heitkamp, PhD    805-879-5091    hheitkam@ridleytreecc.org    Principal Investigator: Daniel R Greenwald, MD          James R. Berenson M.D. Inc. Recruiting West Hollywood, California, United States, 90069 Contact: Regina Swift, R.N    310-623-1227    rswift@berensononcology.com    Principal Investigator: James R Berenson, MD          United States, Florida Millennium Oncology Research Clinic Recruiting Pembroke Pines, Florida, United States, 33024 Contact: Maria Contreras, MD    954-266-7885    mcontreras@millenniumoncologyfl.com    Principal Investigator: Isaac Levy, MD          United States, Maryland Regional Cancer Care Associates (RCCA) MD, LLC Recruiting Bethesda, Maryland, United States, 20817 Contact: Natalie Bongiorno, RN    301-571-2016    nbongiorno@regionalcancercare.org    Principal Investigator: Ralph Boccia, MD Less <<
NCT02593929 Head and Neck Squamous Cell Ca... More >>rcinoma Less << Early Phase 1 Withdrawn - -
NCT01790295 Primary Myelofibrosis ... More >> Post Polycythemia Vera Myelofibrosis Post Essential Thrombocythemia Myelofibrosis Less << Phase 2 Active, not recruiting February 2021 United States, Georgia ... More >> Emory Hospital Atlanta, Georgia, United States, 30322 United States, Illinois Northwestern University, Robert h. Lurie Comprehensive Cancer Center Chicago, Illinois, United States, 60611 United States, Kansas University of Kansas Cancer Center Westwood, Kansas, United States, 66205 United States, New York Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 United States, North Carolina Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States, 27103 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 Canada Princess Margaret Cancer Centre, University of Toronto Toronto, Canada, M5G 2M9 United Kingdom University of Oxford Oxford, United Kingdom, OX3 9DS Less <<
NCT02267278 Myeloproliferative Diseases Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03616184 Graft-versus-host-disease (GVH... More >>D) Less << PHASE2 COMPLETED 2023-06-12 Moffitt Cancer Center, Tampa, ... More >>Florida, 33612, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Ohio State University, Columbus, Ohio, 43210, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States Less <<
NCT03681561 Hodgkin Lymphoma Phase 1 Phase 2 Recruiting March 2024 United States, Minnesota ... More >> University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 Contact: Erin Zielinski    612-624-0937    eezielin@umn.edu    Principal Investigator: Veronika Bachanova, MD Less <<
NCT01895842 Leukemia PHASE1 COMPLETED 2019-04-02 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT03123588 MPN (Myeloproliferative Neopla... More >>sms) Less << Phase 2 Recruiting June 2020 -
NCT03514069 Glioma Gliobl... More >>astoma Less << Phase 1 Recruiting December 2020 United States, Ohio ... More >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44195 Contact: Manmeet Ahluwalia, MD    866-223-8100    CancerCenterResearch@ccf.org    Principal Investigator: Manmeet Ahluwalia, MD Less <<
NCT02493530 Myelofibrosis ... More >> Polycythemia Vera Less << Phase 1 Recruiting December 2019 United States, Arizona ... More >> Mayo Clinic - Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Clinical Trials Office    855-776-0015       Principal Investigator: Ruben Mesa, MD          United States, Colorado University of Colorado Cancer Center Recruiting Aurora, Colorado, United States, 80045 Contact: Clinical Trials Office    720-848-0018       Principal Investigator: Daniel A Pollyea, MD, MS          United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Clinical Trials Office    800-811-8480       Principal Investigator: Michael R Savona, MD          United States, Wisconsin Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Clinical Trials Office    414-805-1118       Principal Investigator: Laura C. Michaelis, MD Less <<
NCT03286530 Acute Myeloid Leukemia|Acute M... More >>yeloid Leukemia in Remission|Allogeneic Stem Cell Transplantation Less << PHASE2 RECRUITING 2025-12-26 Beth Israel Deaconess Medical ... More >>Center, Boston, Massachusetts, 02115, United States|Massachusetts General Hospital, Boston, Massachusetts, 02115, United States|Washington University, Saint Louis, Missouri, 63130, United States|The Ohio State University, Columbus, Ohio, 43210, United States|Vanderbilt University, Nashville, Tennessee, 37235, United States|Medical College of Wisconsin, Wauwatosa, Wisconsin, 53226, United States Less <<
NCT03041636 Malignant Neoplasms Stated as ... More >>Primary Lymphoid Haematopoietic Other Diseases of Blood and Blood-Forming Organs Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Less << Phase 2 Recruiting March 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       zestrov@mdanderson.org Less <<
NCT03427866 Myelofibrosis PHASE2 ACTIVE_NOT_RECRUITING 2025-05-25 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02214, United States|Washington University, Saint Louis, Missouri, 63130, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210, United States|Vanderbilt University, Nashville, Tennessee, 37235, United States Less <<
NCT03722407 Chronic Myelomonocytic Leukemi... More >>a|Leukemia Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-09-01 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21231, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Weill Medical College of Cornell University, New York, New York, 10021, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States Less <<
NCT02784496 Myelofibrosis Phase 2 Active, not recruiting September 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02928978 Ductal Carcinoma In Situ ... More >> Atypical Lobular Hyperplasia Atypical Ductal Hyperplasia Lobular Carcinoma In Situ Less << Phase 2 Recruiting January 2020 United States, Texas ... More >> Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Kristen Otte    713-798-8874    clinical-research@breastcenter.tmc.edu    Principal Investigator: Julie Nangia, M.D.          Sub-Investigator: Mothaffar Rimawi, M.D.          Sub-Investigator: Matthew Ellis, M.D.          Sub-Investigator: Maryam Nemati Shaefee, M.D.          Sub-Investigator: C. Kent Osborne, M.D.          Sub-Investigator: Angela Coscio, M.D. Less <<
NCT02912754 Leukemia, Lymphocytic, Chronic... More >>, B-Cell Less << Phase 1 Phase 2 Not yet recruiting August 2019 Canada, Ontario ... More >> Sunnybrook Odette Cancer Center Not yet recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Geetha Geetha Yogendran, BSc    416-480-5000 ext 89565    geetha.yogendran@sunnybrook.ca    Contact: Lindsay McCaw, MSc    416-480-6100 ext 4244    lindsay.mccaw@sunnybrook.ca    Principal Investigator: david e spaner, MD          Sunnybrook Odette Cancer Center Toronto, Ontario, Canada, M4N3M5 Less <<
NCT02809976 Vitiligo Phase 2 Completed - United States, Massachusetts ... More >> Tufts Medical Center Boston, Massachusetts, United States, 02111 Less <<
NCT02041429 Recurrent Breast Cancer ... More >> Metastatic Breast Cancer Less << Phase 1 Phase 2 Active, not recruiting January 2021 United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT04331665 COVID-19|Pneumonia TERMINATED 2021-03-24 Princess Margaret Cancer Centr... More >>e, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT05592015 T-Cell Large Granular Lymphocy... More >>te Leukemia Less << PHASE2 RECRUITING 2025-12-31 Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States Less <<
NCT05600855 Transplant-Related Disorder PHASE2 COMPLETED 2024-12-01 Institute of Hematology & Bloo... More >>d Diseases Hospital, Tianjin, Tianjin, 300020, China Less <<
NCT03959371 Myelofibrosis UNKNOWN 2021-12-31 ASST Papa Giovanni XXIII, Berg... More >>amo, Italy|U.O. Ematologia, ASST Spedali Civili, Brescia, Italy|U.S.D. Trapianti di Midollo Osseo, ASST Spedali Civili, Brescia, Italy|U.O.C. di Ematologia Clinica, ASST Lecco, Lecco, Italy|U.O. Ematologia, ASST Fatebenefratelli-Sacco, Milan, Italy|U.O. Ematologia, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy|U.O. Ematologia, Grande Ospedale Metropolitano Niguarda, Milan, Italy|U.O. Ematologia, Humanicas Cancer Center, Milan, Italy|U.O. Ematologia, Ospedale San Raffaele, Milan, Italy|U.O. Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|Clinica Ematologica, Ospedale San Gerardo, Monza, Italy|Ospedale di Circolo, ASST Sette Laghi, Varese, 21100, Italy Less <<
NCT01965119 Relapsed or Refractory Hodgkin... More >> Lymphoma|Primary Mediastinal Large B-cell Lymphoma Less << PHASE2 COMPLETED 2018-09-18 Busan University Hospital, Bus... More >>an, Korea, Republic of|Dong-A University, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Asan Medical Center, Seoul, 138-736, Korea, Republic of|Korean Cancer Center Hospital, Seoul, 139-706, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, 220-701, Korea, Republic of Less <<
NCT01877005 Hodgkin's Lymphoma PHASE2 COMPLETED 2018-06-12 UCL Louvain St Luc, Brussels, ... More >>10200, Belgium|Université Catholique de Louvain Mont Godinne, Yvoir, 5530, Belgium|Chu Cote de Nacre, Caen, 14000, France|Hopital Henri Mondor, Creteil, 94010, France|Chu Dijon, Dijon, 21000, France|Chru de Lille, Lille, 59037, France|Centre Leon Berard, Lyon, 69373, France|Centre Hospitalier Lyon Sud, Lyon, 69495, France|CHU de Nantes, Hotel Dieu, Nantes, 44093, France|Centre Henri Becquerel, Rouen, 76038, France Less <<
NCT04348071 COVID-19 PHASE2|PHASE3 WITHDRAWN 2025-10-21 -
NCT05722912 Graft-versus-host Disease (GVH... More >>D) Less << APPROVED_FOR_MARKETING - -
NCT05398809 Autoimmune Polyendocrinopathy ... More >>Candidiasis Ectodermal Dystrophy (Apeced)|Alopecia Areata Less << PHASE2 RECRUITING 2027-12-01 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT05998408 Severe Aplastic Anemia|Single ... More >>Lineage Cytopenias, T-LGL|Hypoplastic MDS Less << PHASE1|PHASE2 RECRUITING 2032-06-03 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT05663827 Steroid Refractory GVHD PHASE3 COMPLETED 2022-11-30 Chang Gung Memorial Hospital, ... More >>Taoyuan, 333, Taiwan Less <<
NCT04338958 Covid-19 PHASE2 COMPLETED 2021-07-15 SRH Wald-Klinikum Gera GmbH, G... More >>era, 07548, Germany|University Hospital Jena, Jena, 07747, Germany|UKSH, Campus Lübeck, Lübeck, 23538, Germany|Klinikum der Landeshauptstadt Stuttgart gK?R, Stuttgart, 70174, Germany|Universit?tsklinikum Ulm, Ulm, 89081, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, 78052, Germany Less <<
NCT05599256 Transplant-Related Disorder PHASE2 RECRUITING 2025-12-01 Institute of Hematology & Bloo... More >>d Diseases Hospital, Tianjin, Tianjin, 300020, China Less <<
NCT06695507 Chronic Graft Versus Host Dise... More >>ase Less << PHASE1 RECRUITING 2025-06-28 Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less <<
NCT06244862 Hemophagocytic Syndromes PHASE2 NOT_YET_RECRUITING 2026-02-01 -
NCT06008808 Graft Vs Host Disease|Graft-ve... More >>rsus-host-disease|Graft Versus Host Disease Less << PHASE1 RECRUITING 2026-12-11 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT05121142 Acute-graft-versus-host Diseas... More >>e|Chronic Graft-versus-host-disease|Solid Organ Transplant Less << PHASE1 COMPLETED 2023-05-13 Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less <<
NCT05566535 Polycythemia Vera UNKNOWN 2024-08-01 -
NCT04908280 Discoid Lupus Erythematosus PHASE2 COMPLETED 2024-03-04 UR Medicine Dermatology Colleg... More >>e Town, Rochester, New York, 14642, United States Less <<
NCT05413356 Bronchiolitis Obliterans Syndr... More >>ome|Hematologic Malignancy Less << PHASE2 UNKNOWN 2025-01-01 The first Affiliated Hospital ... More >>of Zhejiang University, Hangzhou, Zhejiang, 310000, China Less <<
NCT05762874 Myelofibrosis NOT_YET_RECRUITING 2025-06-25 -
NCT06462469 Steroid-refractory Acute Graft... More >> Versus Host Disease Less << PHASE4 RECRUITING 2026-11-05 Novartis Investigative Site, G... More >>uangzhou City, Guangdong, 510000, China|Novartis Investigative Site, Guangzhou, Guangdong, 510515, China|Novartis Investigative Site, Zhengzhou, Henan, 450052, China|Novartis Investigative Site, Wuhan, Hubei, 430030, China|Novartis Investigative Site, Chang Chun, Jilin, 130021, China|Novartis Investigative Site, Chengdu, Sichuan, 610072, China|Novartis Investigative Site, Hangzhou, Zhejiang, 310003, China|Novartis Investigative Site, Beijing, 100028, China|Novartis Investigative Site, Beijing, 100034, China|Novartis Investigative Site, Beijing, 100039, China|Novartis Investigative Site, Dalian, 116000, China|Novartis Investigative Site, Fuzhou, 350001, China|Novartis Investigative Site, Shanghai, 200025, China|Novartis Investigative Site, Tianjin, 300020, China Less <<
NCT04337359 Severe/Very Severe COVID-19 Il... More >>lness Less << NO_LONGER_AVAILABLE - -
NCT01392443 Primary Myelofibrosis (MF)|Pos... More >>t-Polycythemia Vera (PV) MF|Post-Essential Thrombocythemia (ET) MF Less << PHASE2 COMPLETED 2017-10-31 Novartis Investigative Site, B... More >>eijing, Beijing, 100730, China|Novartis Investigative Site, Guangzhou, Guangdong, 51000, China|Novartis Investigative Site, Wuhan, Hubei, 430030, China|Novartis Investigative Site, Nanjing, Jiangsu, 210029, China|Novartis Investigative Site, Suzhou, Jiangsu, 215006, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Tianjin, Tianjin, 300020, China|Novartis Investigative Site, Hangzhou, Zhejiang, 310003, China|Novartis Investigative Site, Jinan, 250012, China|Novartis Investigative Site, Shanghai, 200025, China|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Maebashi city, Gunma, 371 8511, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, 920-8641, Japan|Novartis Investigative Site, Tsu-city, Mie, 514-8507, Japan|Novartis Investigative Site, Suita city, Osaka, 565 0871, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, 113 8655, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160 8582, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160-0023, Japan|Novartis Investigative Site, Seoul, Korea, 06351, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, 06591, Korea, Republic of|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Seoul, 03722, Korea, Republic of|Novartis Investigative Site, Kaohsiung, 833, Taiwan|Novartis Investigative Site, Taipei, 10048, Taiwan|Novartis Investigative Site, Taoyuan, 333, Taiwan Less <<
NCT04446806 Safety and Efficacy PHASE4 UNKNOWN 2021-05-31 First Affiliated Hospital, Soo... More >>chow University, Suzhou, Jiangsu, 215000, China Less <<
NCT00617994 Psoriasis PHASE2 COMPLETED 2009-05-31 Fridley, Minnesota, 55432, Uni... More >>ted States|Rochester, New York, 14623, United States|Austin, Texas, 78759, United States|College Station, Texas, 77840, United States Less <<
NCT05269771 Polycythemia Vera AVAILABLE - -
NCT04492618 Necrobiosis Lipoidica PHASE2 COMPLETED 2022-03-16 Mayo Clinic in Arizona, Scotts... More >>dale, Arizona, 85259, United States Less <<
NCT02164500 Recurrent Classical Hodgkin Ly... More >>mphoma Less << PHASE2 COMPLETED 2019-05-17 1st Dept. of Medicine, Cologne... More >> University Hospital, Cologne, 50924, Germany Less <<
NCT04644211 Essential Thrombocythemia|Poly... More >>cythemia Vera Less << PHASE2 RECRUITING 2025-12-24 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02115, United States|Beth-Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT02072057 Cancer Cachexia PHASE2 TERMINATED 2018-11-30 Division of Hematology/Oncolgy... More >>, University Clinic of Medicine, Kantonsspital Aarau AG, Aarau, AG, 5001, Switzerland|Division of Hematology/Oncology, Kantonsspital Olten, Olten, SO, 4600, Switzerland Less <<
NCT05021276 Safety and Efficacy PHASE4 UNKNOWN 2022-12-15 The First Affiliated Hospital ... More >>of Soochow University, Suzhou, Jiangsu, 215006, China Less <<
NCT04745637 Primary Myelofibrosis (PMF)|Po... More >>st Polycythemia Myelofibrosis (PPV MF)|Thrombocythemia Myelofibrosis (PET-MF)|Severe/very Severe COVID-19 Illness|Polycythemia Vera (PV)|Steroid Refractory Acute Graft Versus Host Disease (SR AGVHD)|Steroid Refractory Chronic Graft Versus Host Disease (SR CGVHD) Less << AVAILABLE - -
NCT05762640 Haemophagocytic Lymphohistiocy... More >>tosis Less << PHASE2 NOT_YET_RECRUITING 2025-11-27 -
NCT05909943 Neuromyelitis Optica Spectrum ... More >>Disorder Relapse Less << PHASE1|PHASE2 WITHDRAWN 2026-08-01 Tianjin Medical University Gen... More >>eral Hospital, Tianjin, Tianjin, 300052, China Less <<
NCT04908735 Hematopoietic Stem Cell Transp... More >>lant (HSCT)|Bronchiolitis Obliterans (BO) Less << PHASE2 RECRUITING 2025-11-25 University of Minnesota, Minne... More >>apolis, Minnesota, 55455, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States Less <<
NCT05410470 Myelofibrosis COMPLETED 2025-12-21 -
NCT04807777 Advanced Cutaneous Squamous Ce... More >>ll Carcinoma Less << PHASE2 TERMINATED 2023-10-04 Columbia University Irving Med... More >>ical Center, New York, New York, 10032, United States Less <<
NCT04355793 COVID-19 NO_LONGER_AVAILABLE - -
NCT05293717 Chronic Hand Dermatitis PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2024-12-31 UR Medicine Dermatology Colleg... More >>e Town, Rochester, New York, 14642, United States Less <<
NCT03801434 BCR-JAK2 Fusion Protein Expres... More >>sion|Blasts 20 Percent or Less of Peripheral Blood White Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|Blasts Under 20 Percent of Bone Marrow Nucleated Cells|Chronic Eosinophilic Leukemia, Not Otherwise Specified|Eosinophilia|Hepatomegaly|Hypereosinophilic Syndrome|JAK2 Gene Mutation|Splenomegaly|TEL-JAK2 Fusion Protein Expression Less << PHASE2 RECRUITING 2025-11-30 Stanford Cancer Institute Palo... More >> Alto, Palo Alto, California, 94304, United States|OHSU Knight Cancer Institute, Portland, Oregon, 97201, United States|University of Utah, Salt Lake City, Utah, 84112, United States|Fred Hutchinson cancer research center, Seattle, Washington, 98109, United States Less <<
NCT05998395 Kohlmeier Degos Disease With N... More >>eurologic Involvement Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-03-15 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT05447260 Myelofibrosis PHASE4 UNKNOWN 2023-12-10 Qilu Hospital of Shandong Univ... More >>ersity, Jinan, Shandong, China Less <<
NCT06075225 GVHD|Acute Stem Cell Transplan... More >>t Complications Less << PHASE2 NOT_YET_RECRUITING 2026-09-30 West China Hospital, Sichuan U... More >>niversity, Chendu, Sichuan, 610041, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.26mL

0.65mL

0.33mL

16.32mL

3.26mL

1.63mL

32.64mL

6.53mL

3.26mL

References

 

Historical Records

Categories